Skip to main content

Table 2 Dosing information

From: Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Radiotracer Injected Dose (MBq) Mass dose limit Number of subjects scanned Clinically detectable pharmacological effects in humans
[11C]Radiotracers
 [11C]ACE 740 None 475 No
 [11C]ACHC 740 ≤5000 μg/subject 2 No
 [11C]BMP 444 ≤4625 μg/subject 65 No
 [11C]BUT 555 ≤125 μg/kg 0a a
 [11C]CFN 555 ≤0.03 μg/kg 1492 No
 [11C]CHO 592 None 44 No
 [11C]DASB 666 ≤8 μg/subject 179 No
 [11C]DTBZ 555 ≤50 μg/subject 1823 No
 [11C]EPI 740 < 9 μg/subject epinephrine & ≤1 μg/subject norepinephrine precursor 96 No
 [11C]FMZ 370 ≤50 μg/subject 668 No
 [11C]HED 666 ≤50 μg/subjectb 643 No
 [11C]LY2795050 555 ≤10 μg/subject 0c c
 [11C]MET 444 None 129 No
 [11C]MTBZ 580 ≤10 μg/subject 6 No
 [11C]MPH 666 ≤25 μg/subject 170 No
 [11C]NMBP 740–1480 ≤127 μg/subjectd 59 No
 [11C]OMAR 666 0.14 μg/kg 0e e
 [11C]PALM 740 None 8 No
 [11C]PBR28 666 ≤10 μg/subject 34 No
 [11C]PiB 666 ≤13 μg/subject 592 No
 [11C]PE2I 555 ≤6.3 μg/subject 1 No
 [11C]PHEN 740 ≤6800 μg/subject 29 No
 [11C]PK11195 888 ≤420 μg/subject 118 No
 [11C]PMP 555 ≤200 μg/subject 801 No
 [11C]RAC 555 ≤50 μg/subject 627 No
 [11C]Ro-54,864 555 ≤160 μg/subject 6 No
 [11C]SARC 592 None 20 No
 [11C]SCOP 1480 ≤50 μg/subject 14 No
 [11C]TBZ 1018 ≤10 μg/subject 2 No
 [11C]TRB 1110 ≤31 μg/subject 26 No
 [11C]WAY-100365 555 ≤15 μg/subject 51 No
[18F]Radiotracers
 [18F]AV1451 370 ≤20 μg/subject 92 No
 [18F]ASEM 370 ≤0.67 μg/subject 1 No
 Auxumin 370 ≤20 μg/subject 228f No
 [18F]FAZA 296 ≤3.5 μg/subject 14 No
 [18F]FDG 185–296 None 6804 No
 [18F]FDOPA 148 ≤15 μg/subject 0g g
 [18F]FEOBV 296 ≤1.23 μg/subject 308 No
 [18F]FCH 222 ≤100 μg/subject 67 No
 Amyvid 370 ≤50 μg/subject 222 No
 [18F]FLT 370 ≤20 μg/subject 8 No
 [18F]FLBT 296 ≤0.02 μg/kg 92 No
 Vizamyl 370 ≤20 μg/subject 11 No
 [18F]FMISO 370 ≤15 μg/subject 8 No
 [18F]FP-TBZ 370 ≤7.5 μg/subject 23 No
 [18F]GBR 148 ≤900 μg/subject 2 No
 [18F]MHPG 241 ≤10 μg/subject 17 No
 [18F]MPPF 259 ≤2 μg/subject 34 No
 [18F]NaF 222 None 9 No
 [18F]NML 370 ≤10 μg/subject 6 No
 [18F]PHPG 241 ≤10 μg/subject 15 No
Other Radiotracers
 [13N]NH3 740 None 1472 No
 [15O]Water 555 None 1153 No
 NETSPOT 200 ≤40 μg/subject 981f No
 [68Ga]PSMA-11 185 ≤10 μg/subject 751f No
  1. a[11C]Butanol is validated for clinical production but studies have not yet commenced. We do not expect clinically detectable pharmacological effects as the mass limit (≤125 μg/kg) was selected since it is 1000 times below the NOAEL (125 mg/kg, see: Wagner 2005); b combined mass of HED and metaraminol precursor must be ≤50 μg/subject; c [11C]LY2795050 is validated for clinical production but studies have not yet commenced at UM. We do not expect clinically detectable pharmacological effects as the mass limit (≤10 μg/subject) has been used without significant adverse events at other institutions (see: Naganawa et al. 2015); d See published limits (Yoshida et al. 1998); e [11C]OMAR is validated for clinical production but studies have not yet commenced at UM. We do not expect clinically detectable pharmacological effects as the mass limit (≤0.14 μg/kg) has been used without significant adverse events at other institutions (see: Wong et al. 2010); f Includes subjects numbers scanned for clinical care and research; g [18F]FDOPA is validated for clinical production but studies have not yet commenced. We do not expect clinically detectable pharmacological effects as the mass limit (≤15 μg/subject) is significantly less than administered masses historically used when employing the electrophilic synthesis of [18F]FDOPA (13 mg/62 kg subject, see: Chevalme et al. 2007)